

# Latin America, Middle East & Africa Pharmacogenomics Market (2019-2025)

https://marketpublishers.com/r/L6196FEFDA6EN.html

Date: June 2019 Pages: 104 Price: US\$ 1,500.00 (Single User License) ID: L6196FEFDA6EN

### Abstracts

The Latin America, Middle East and Africa Pharmacogenomics Market would witness market growth of 9.9% CAGR during the forecast period (2019–2025).

Chronic diseases are spreading at an alarming rate which has consequently boosted the demand for precision and personalized medicine. Pharmacogenomics has been widely recognized as a fundamental step in personalized medicine and growing demand for personalized medicine is propelling the growth of the global pharmacogenomics market.

Pharmacogenomics is expected to facilitate the treatment of a wide spectrum of diseases such as cardiovascular diseases, Alzheimer disease, HIV/AIDS, and cancer among others. An upsurge in the investments for technology advancements is primarily poised to revolutionize the pharmacogenomics market. Furthermore, it also supports the customization of medicine doses according to a person's genetics.

Based on Technology, the market is segmented into Sequencing, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, Microarray and Others. Based on Application, the market is segmented into Oncology, Psychiatry, Infectious Diseases, Neurological Diseases, Pain management, Cardiovascular Diseases and Others. Based on End User, the market is segmented into Hospitals and Clinics, Research Institutions, and Academic Institutes. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Empire Genomics LLC, Illumina, Inc., oneome LLC, Myriad Genetics Inc., Thermo Fisher Scientific, Inc., Teva



Pharmaceuticals Industries Ltd., Bayer AG, Opko Health, Inc., and Becton, Dickinson and Company.

Scope of the Study

Market Segmentation:

By Application

Sequencing

Polymerase Chain Reaction

Electrophoresis

Mass Spectrometry

Microarray

Others

#### By Application

Oncology

Psychiatry

**Infectious Diseases** 

**Neurological Diseases** 

Pain management

Cardiovascular Diseases

Others



#### By End User

Hospitals and Clinics

**Research Institutions** 

Academic Institutes

#### By Country

Brazil

Argentina

UAE

Saudi Arabia

South Africa

Nigeria

Rest of LAMEA

**Companies Profiled** 

Abbott Laboratories

#### **Empire Genomics LLC**

Illumina, Inc.

Oneome LLC

Myriad Genetics Inc.

Thermo Fisher Scientific, Inc.



Teva Pharmaceuticals Industries Ltd.

Bayer AG

Opko Health, Inc.

Becton, Dickinson and Company



### Contents

#### **CHAPTER 1. MARKET SCOPE & METHODOLOGY**

- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 LAMEA Pharmacogenomics Market, by Application
- 1.4.2 LAMEA Pharmacogenomics Market, by Application
- 1.4.3 LAMEA Pharmacogenomics Market, by End User
- 1.4.4 LAMEA Pharmacogenomics Market, by Country
- 1.5 Methodology for the research

#### **CHAPTER 2. MARKET OVERVIEW**

- 2.1 Introduction
  - 2.1.1 Overview
- 2.1.2 Market Composition and Scenario
- 2.2 Key Factors Impacting the Market
  - 2.2.1 Market Drivers
  - 2.2.2 Market Restraints

#### CHAPTER 3. LAMEA PHARMACOGENOMICS MARKET BY TECHNOLOGY

- 3.1.1 LAMEA Sequencing Market by Country
- 3.1.2 LAMEA Polymerase Chain Reaction Market by Country
- 3.1.3 LAMEA Electrophoresis Market by Country
- 3.1.4 LAMEA Mass Spectrometry Market by Country
- 3.1.5 LAMEA Microarray Market by Country
- 3.1.6 LAMEA Others Market by Country

#### CHAPTER 4. LAMEA PHARMACOGENOMICS MARKET BY APPLICATION

- 4.1.1 LAMEA Oncology Market by Country
- 4.1.2 LAMEA Psychiatry Market by Country
- 4.1.3 LAMEA Infectious Diseases Market by Country
- 4.1.4 LAMEA Neurological Diseases Market by Country
- 4.1.5 LAMEA Pain Management Market by Country



- 4.1.6 LAMEA Cardiovascular Diseases Market by Country
- 4.1.7 LAMEA Others Market by Country

#### CHAPTER 5. LAMEA PHARMACOGENOMICS MARKET BY END USER

- 5.1.1 LAMEA Hospitals and Clinics Market by Country
- 5.1.2 LAMEA Research Institutions Market by Country
- 5.1.3 LAMEA Academic Institutes Market by Country

#### CHAPTER 6. LAMEA PHARMACOGENOMICS MARKET BY COUNTRY

6.1 Brazil Pharmacogenomics Market6.1.1 Brazil Pharmacogenomics Market by Technology

- 6.1.2 Brazil Pharmacogenomics Market by Application
- 6.1.3 Brazil Pharmacogenomics Market by End User
- 6.2 Argentina Pharmacogenomics Market
- 6.2.1 Argentina Pharmacogenomics Market by Technology
- 6.2.2 Argentina Pharmacogenomics Market by Application
- 6.2.3 Argentina Pharmacogenomics Market by End User
- 6.3 UAE Pharmacogenomics Market
- 6.3.1 UAE Pharmacogenomics Market by Technology
- 6.3.2 UAE Pharmacogenomics Market by Application
- 6.3.3 UAE Pharmacogenomics Market by End User
- 6.4 Saudi Arabia Pharmacogenomics Market
- 6.4.1 Saudi Arabia Pharmacogenomics Market by Technology
- 6.4.2 Saudi Arabia Pharmacogenomics Market by Application
- 6.4.3 Saudi Arabia Pharmacogenomics Market by End User
- 6.5 South Africa Pharmacogenomics Market
- 6.5.1 South Africa Pharmacogenomics Market by Technology
- 6.5.2 South Africa Pharmacogenomics Market by Application
- 6.5.3 South Africa Pharmacogenomics Market by End User
- 6.6 Nigeria Pharmacogenomics Market
- 6.6.1 Nigeria Pharmacogenomics Market by Technology
- 6.6.2 Nigeria Pharmacogenomics Market by Application
- 6.6.3 Nigeria Pharmacogenomics Market by End User
- 6.7 Rest of LAMEA Pharmacogenomics Market
  - 6.7.1 Rest of LAMEA Pharmacogenomics Market by Technology
  - 6.7.2 Rest of LAMEA Pharmacogenomics Market by Application
- 6.7.3 Rest of LAMEA Pharmacogenomics Market by End User



#### **CHAPTER 7. COMPANY PROFILES**

- 7.1 ABBOTT Laboratories
  - 7.1.1 Company Overview
  - 7.1.2 Financial Analysis
  - 7.1.3 Segmental and Regional Analysis
  - 7.1.4 Research & Development Expense
  - 7.1.5 Recent strategies and developments:
  - 7.1.5.1 Collaborations, partnerships and agreements:
  - 7.1.5.2 Product launches:
  - 7.1.5.3 Acquisition and mergers:
- 7.1.6 SWOT Analysis
- 7.2 Empire Genomics LLC
- 7.2.1 Company Overview
- 7.3 Illumina, Inc.
  - 7.3.1 Company Overview
  - 7.3.2 Financial Analysis
  - 7.3.3 Regional & Segmental Analysis
  - 7.3.4 Research& Development Expenses
  - 7.3.5 Recent strategies and developments:
  - 7.3.5.1 Collaborations, partnerships and agreements:
  - 7.3.5.2 Product launches:
  - 7.3.5.3 Acquisition and mergers:
- 7.4 OneOme LLC
- 7.4.1 Company Overview
- 7.5 Myriad Genetics Inc.
  - 7.5.1 Company Overview
  - 7.5.2 Financial Analysis
  - 7.5.3 Segmental and Regional Analysis
  - 7.5.4 Research & Development Expense
  - 7.5.5 Recent strategies and developments:
  - 7.5.5.1 Collaborations, partnerships and agreements:
  - 7.5.5.2 Product launches:
- 7.6 Thermo Fischer Scientific, Inc.
  - 7.6.1 Company Overview
  - 7.6.2 Financial Analysis
  - 7.6.3 Segmental and Regional Analysis
  - 7.6.4 Research & Development Expense



- 7.6.5 Recent strategies and developments:
  - 7.6.5.1 Collaborations, partnerships and agreements:
  - 7.6.5.2 Acquisition and mergers:
- 7.6.6 SWOT Analysis
- 7.7 Teva Pharmaceuticals Industries Ltd.
  - 7.7.1 Company Overview
  - 7.7.2 Financial Analysis
  - 7.7.3 Segmental Analysis
  - 7.7.4 Research & Development Expense
  - 7.7.5 Recent strategies and developments:
  - 7.7.5.1 Product launches:
- 7.8 Bayer AG
  - 7.8.1 Company Overview
  - 7.8.2 Financial Analysis
  - 7.8.3 Segmental and Regional Analysis
  - 7.8.4 Research & Development Expense
  - 7.8.5 Recent strategies and developments:
  - 7.8.5.1 Collaborations, partnerships and agreements:
  - 7.8.6 SWOT Analysis
- 7.9 Opko Health, Inc. (GeneDx, Inc.)
  - 7.9.1 Company Overview
  - 7.9.2 Financial Analysis
  - 7.9.3 Research & Development Expense
  - 7.9.4 Recent strategies and developments:
    - 7.9.4.1 Collaborations, partnerships and agreements:
  - 7.9.4.2 Product launches:
- 7.1 Becton, Dickinson and Company
  - 7.10.1 Company Overview
  - 7.10.2 Financial Analysis
  - 7.10.3 Segmental and Regional Analysis
  - 7.10.4 Research & Development Expense
  - 7.10.5 Recent strategies and developments:
  - 7.10.5.1 Collaborations, partnerships and agreements:
  - 7.10.5.2 Acquisition and mergers:
  - 7.10.5.3 Product launches:
  - 7.10.6 SWOT Analysis





### **List Of Tables**

#### LIST OF TABLES

TABLE 1 LAMEA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION TABLE 2 LAMEA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION TABLE 3 LAMEA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, **USD MILLION** TABLE 4 LAMEA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION TABLE 5 LAMEA SEQUENCING MARKET BY COUNTRY, 2015 - 2018, USD MILLION TABLE 6 LAMEA SEQUENCING MARKET BY COUNTRY, 2019 - 2025, USD MILLION TABLE 7 LAMEA POLYMERASE CHAIN REACTION MARKET BY COUNTRY, 2015 -2018, USD MILLION TABLE 8 LAMEA POLYMERASE CHAIN REACTION MARKET BY COUNTRY, 2019 -2025, USD MILLION TABLE 9 LAMEA ELECTROPHORESIS MARKET BY COUNTRY, 2015 - 2018, USD MILLION TABLE 10 LAMEA ELECTROPHORESIS MARKET BY COUNTRY, 2019 - 2025, USD MILLION TABLE 11 LAMEA MASS SPECTROMETRY MARKET BY COUNTRY, 2015 - 2018, **USD MILLION** TABLE 12 LAMEA MASS SPECTROMETRY MARKET BY COUNTRY, 2019 - 2025, **USD MILLION** TABLE 13 LAMEA MICROARRAY MARKET BY COUNTRY, 2015 - 2018, USD MILLION TABLE 14 LAMEA MICROARRAY MARKET BY COUNTRY, 2019 - 2025, USD MILLION TABLE 15 LAMEA OTHERS MARKET BY COUNTRY, 2015 - 2018, USD MILLION TABLE 16 LAMEA OTHERS MARKET BY COUNTRY, 2019 - 2025, USD MILLION TABLE 17 LAMEA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, **USD MILLION** TABLE 18 LAMEA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, **USD MILLION** TABLE 19 LAMEA ONCOLOGY MARKET BY COUNTRY, 2015 - 2018, USD MILLION TABLE 20 LAMEA ONCOLOGY MARKET BY COUNTRY, 2019 - 2025, USD MILLION TABLE 21 LAMEA PSYCHIATRY MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 22 LAMEA PSYCHIATRY MARKET BY COUNTRY, 2019 - 2025, USD



MILLION

TABLE 23 LAMEA INFECTIOUS DISEASES MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 24 LAMEA INFECTIOUS DISEASES MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 25 LAMEA NEUROLOGICAL DISEASES MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 26 LAMEA NEUROLOGICAL DISEASES MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 27 LAMEA PAIN MANAGEMENT MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 28 LAMEA PAIN MANAGEMENT MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 29 LAMEA CARDIOVASCULAR DISEASES MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 30 LAMEA CARDIOVASCULAR DISEASES MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 31 LAMEA OTHERS MARKET BY COUNTRY, 2015 - 2018, USD MILLION TABLE 32 LAMEA OTHERS MARKET BY COUNTRY, 2019 - 2025, USD MILLION TABLE 33 LAMEA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION

TABLE 34 LAMEA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION

TABLE 35 LAMEA HOSPITALS AND CLINICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 36 LAMEA HOSPITALS AND CLINICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 37 LAMEA RESEARCH INSTITUTIONS MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 38 LAMEA RESEARCH INSTITUTIONS MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 39 LAMEA ACADEMIC INSTITUTES MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 40 LAMEA ACADEMIC INSTITUTES MARKET BY COUNTRY, 2019 - 2025, USD MILLION

TABLE 41 LAMEA PHARMACOGENOMICS MARKET BY COUNTRY, 2015 - 2018, USD MILLION

TABLE 42 LAMEA PHARMACOGENOMICS MARKET BY COUNTRY, 2019 - 2025, USD MILLION



TABLE 43 BRAZIL PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION TABLE 44 BRAZIL PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION TABLE 45 BRAZIL PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 -2018, USD MILLION TABLE 46 BRAZIL PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 -2025. USD MILLION TABLE 47 BRAZIL PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, **USD MILLION** TABLE 48 BRAZIL PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION TABLE 49 BRAZIL PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, **USD MILLION** TABLE 50 BRAZIL PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION TABLE 51 ARGENTINA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION TABLE 52 ARGENTINA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION TABLE 53 ARGENTINA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 -2018, USD MILLION TABLE 54 ARGENTINA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 -2025, USD MILLION TABLE 55 ARGENTINA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 -2018, USD MILLION TABLE 56 ARGENTINA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 -2025, USD MILLION TABLE 57 ARGENTINA PHARMACOGENOMICS MARKET BY END USER, 2015 -2018, USD MILLION TABLE 58 ARGENTINA PHARMACOGENOMICS MARKET BY END USER, 2019 -2025, USD MILLION TABLE 59 UAE PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION TABLE 60 UAE PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION TABLE 61 UAE PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION TABLE 62 UAE PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION TABLE 63 UAE PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, **USD MILLION** TABLE 64 UAE PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025,



USD MILLION

TABLE 65 UAE PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION

TABLE 66 UAE PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION

TABLE 67 SAUDI ARABIA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION

TABLE 68 SAUDI ARABIA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION

TABLE 69 SAUDI ARABIA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION

TABLE 70 SAUDI ARABIA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION

TABLE 71 SAUDI ARABIA PHARMACOGENOMICS MARKET BY APPLICATION,2015 - 2018, USD MILLION

TABLE 72 SAUDI ARABIA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION

TABLE 73 SAUDI ARABIA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION

TABLE 74 SAUDI ARABIA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION

TABLE 75 SOUTH AFRICA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION

TABLE 76 SOUTH AFRICA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION

TABLE 77 SOUTH AFRICA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 - 2018, USD MILLION

TABLE 78 SOUTH AFRICA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION

TABLE 79 SOUTH AFRICA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION

TABLE 80 SOUTH AFRICA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 - 2025, USD MILLION

TABLE 81 SOUTH AFRICA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION

TABLE 82 SOUTH AFRICA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION

TABLE 83 NIGERIA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION TABLE 84 NIGERIA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION



TABLE 85 NIGERIA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2015 -2018. USD MILLION TABLE 86 NIGERIA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 -2025, USD MILLION TABLE 87 NIGERIA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 -2018. USD MILLION TABLE 88 NIGERIA PHARMACOGENOMICS MARKET BY APPLICATION, 2019 -2025. USD MILLION TABLE 89 NIGERIA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION TABLE 90 NIGERIA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, **USD MILLION** TABLE 91 REST OF LAMEA PHARMACOGENOMICS MARKET, 2015 - 2018, USD MILLION TABLE 92 REST OF LAMEA PHARMACOGENOMICS MARKET, 2019 - 2025, USD MILLION TABLE 93 REST OF LAMEA PHARMACOGENOMICS MARKET BY TECHNOLOGY. 2015 - 2018, USD MILLION TABLE 94 REST OF LAMEA PHARMACOGENOMICS MARKET BY TECHNOLOGY, 2019 - 2025, USD MILLION TABLE 95 REST OF LAMEA PHARMACOGENOMICS MARKET BY APPLICATION, 2015 - 2018, USD MILLION TABLE 96 REST OF LAMEA PHARMACOGENOMICS MARKET BY APPLICATION. 2019 - 2025, USD MILLION TABLE 97 REST OF LAMEA PHARMACOGENOMICS MARKET BY END USER, 2015 - 2018, USD MILLION TABLE 98 REST OF LAMEA PHARMACOGENOMICS MARKET BY END USER, 2019 - 2025, USD MILLION **TABLE 99 KEY INFORMATION – ABBOTT LABORATORIES** TABLE 100 KEY INFORMATION - EMPIRE GENOMICS LLC TABLE 101 KEY INFORMATION – ILLUMINA, INC. TABLE 102 KEY INFORMATION – ONEOME LLC TABLE 103 KEY INFORMATION – MYRIAD GENETICS INC. TABLE 104 KEY INFORMATION – THERMO FISHER SCIENTIFIC, INC. TABLE 105 KEY INFORMATION - TEVA PHARMACEUTICALS INDUSTRIES LTD. TABLE 106 KEY INFORMATION – BAYER AG TABLE 107 KEY INFORMATION – OPKO HEALTH, INC. TABLE 108 KEY INFORMATION – BECTON, DICKINSON AND COMPANY



## **List Of Figures**

#### LIST OF FIGURES

FIG 1 METHODOLOGY FOR THE RESEARCH FIG 2 SWOT ANALYSIS: ABBOTT LABORATORIES FIG 3 SWOT ANALYSIS: THERMO FISHER SCIENTIFIC, INC. FIG 4 SWOT ANALYSIS: BAYER AG FIG 5 SWOT ANALYSIS: BECTON, DICKINSON AND COMPANY

Latin America, Middle East & Africa Pharmacogenomics Market (2019-2025)



#### I would like to order

Product name: Latin America, Middle East & Africa Pharmacogenomics Market (2019-2025) Product link: <u>https://marketpublishers.com/r/L6196FEFDA6EN.html</u>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

### Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/L6196FEFDA6EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970